abstract |
The present invention relates to a method of reducing tumor cell viability comprising administering to a tumor cell a virus that is not a common human pathogen. Preferably, the virus exhibits different susceptibility in that normal cells are not affected by the virus. This different sensitivity is noticeable in the presence of interferon. Tumor cells are characterized by low or no PKR activity, or PKR-/-, STAT1-/-or both PKR-/-and STAT1-/-. The virus is selected from the group consisting of rhabdovirus and picornavirus, preferably vesicular stomatitis virus (VSV) or a derivative thereof. |